Human rhinovirus VP4: membrane pore-forming capsid protein and conserved target for broadly neutralising antibodies
人鼻病毒 VP4:膜成孔衣壳蛋白和广泛中和抗体的保守靶标
基本信息
- 批准号:MR/S023402/1
- 负责人:
- 金额:$ 81.55万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2019
- 资助国家:英国
- 起止时间:2019 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Human rhinovirus (HRV) infects humans more frequently than any other virus and is responsible for approximately 70% of all subclinical respiratory infections (the common cold) which costs the UK £billions every year. HRV infection is also associated with more serious clinical outcomes such as severe lower respiratory tract infections of infants and exacerbations of chronic lung diseases such as asthma. Viruses must gain entry to host cells for infection to begin and the membrane of the cell presents a barrier which the virus must penetrate. For many viruses, the process by which this is achieved is not well understood. HRV is a very simple virus which makes a good model system for understanding this process in more detail. The virus comprises a single strand of RNA (the virus genome, the blueprint for making new virus) enclosed in a protein shell or capsid. Based on previous experiments we believe that during entry to the cell, a small internal capsid protein called VP4 is released from the virus to form a pore in the membrane through which the RNA is delivered into the cell.The host immune response to a virus infection often produces antibodies which bind to the virus and bring the infection under control. Often a virus can circulate as several strains or types with variation in their outer surface such that antibodies will only recognise and provide protection against one specific virus type. In the case of HRV there are over 100 different types which is thought to explain why colds are so frequent and has limited the prospects of a vaccine. Unlike most of the capsid, the VP4 protein is highly conserved between HRV types and previous experiments showed that antibodies against VP4 can neutralise multiple types of HRV. We will carry out studies to gain novel understanding of how VP4 forms the pore in the membrane, how it emerges from the particle and how antibodies against VP4 can have broadly neutralising activity against multiple types of the virus.
人鼻病毒(HRV)比任何其他病毒更频繁地感染人类,并且负责约70%的所有亚临床呼吸道感染(普通感冒),每年花费英国数十亿英镑。HRV感染还与更严重的临床结果相关,如婴儿严重下呼吸道感染和慢性肺部疾病(如哮喘)的恶化。病毒必须进入宿主细胞才能开始感染,细胞膜是病毒必须穿透的屏障。对于许多病毒来说,实现这一点的过程并不很清楚。HRV是一种非常简单的病毒,它为更详细地理解这一过程提供了一个很好的模型系统。该病毒由包裹在蛋白质外壳或衣壳中的单链RNA(病毒基因组,制造新病毒的蓝图)组成。根据先前的实验,我们认为在病毒进入细胞的过程中,一种叫做VP4的小的内部衣壳蛋白从病毒中释放出来,在细胞膜上形成一个孔,RNA通过这个孔被递送到细胞内。宿主对病毒感染的免疫反应通常会产生抗体,这些抗体与病毒结合并控制感染。通常,一种病毒可以作为几种毒株或类型传播,它们的外表面存在变异,因此抗体只能识别一种特定的病毒类型并提供保护。在HRV的情况下,有超过100种不同的类型,这被认为可以解释为什么感冒如此频繁,并限制了疫苗的前景。与大多数衣壳不同,VP4蛋白在HRV类型之间高度保守,并且先前的实验表明针对VP4的抗体可以中和多种类型的HRV。我们将开展研究,以获得对VP4如何在膜中形成孔的新的理解,它如何从颗粒中出现,以及针对VP4的抗体如何对多种类型的病毒具有广泛的中和活性。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Membrane Interactions and Uncoating of Aichi Virus, a Picornavirus That Lacks a VP4.
- DOI:10.1128/jvi.00082-22
- 发表时间:2022-04-13
- 期刊:
- 影响因子:5.4
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tobias Tuthill其他文献
Tobias Tuthill的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tobias Tuthill', 18)}}的其他基金
Antiviral restriction factors: Understanding determinants of host range and barriers to species-jumping in livestock viral disease
抗病毒限制因素:了解牲畜病毒性疾病宿主范围的决定因素和物种跳跃的障碍
- 批准号:
BB/X009084/1 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Understanding RNA packaging signals in foot-and-mouth disease virus (FMDV) for improved vaccine production
了解口蹄疫病毒 (FMDV) 中的 RNA 包装信号以改进疫苗生产
- 批准号:
BB/V008323/1 - 财政年份:2021
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Host factors controlling foot-and-mouth disease virus (FMDV) replication: towards genetic control of FMD in pigs
控制口蹄疫病毒(FMDV)复制的宿主因素:猪口蹄疫的遗传控制
- 批准号:
BB/T003138/1 - 财政年份:2019
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Improved vaccine manufacture to control foot-and-mouth disease: Production of recombinant vaccines by design
改进疫苗生产以控制口蹄疫:通过设计生产重组疫苗
- 批准号:
BB/N007298/1 - 财政年份:2016
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Picornavirus capsid protein VP4: Essential role in cell entry and conserved antiviral target
小核糖核酸病毒衣壳蛋白 VP4:在细胞进入和保守抗病毒靶点中的重要作用
- 批准号:
MR/K020811/1 - 财政年份:2013
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Foot-and-mouth disease virus entry: RNA release and membrane penetration
口蹄疫病毒进入:RNA 释放和膜渗透
- 批准号:
BB/H018301/1 - 财政年份:2010
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
相似海外基金
Developing a PIV5-based human metapneumovirus (HMPV) vaccine
开发基于 PIV5 的人类偏肺病毒 (HMPV) 疫苗
- 批准号:
10698491 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Novel Hybrid Computational Models to Disentangle Complex Immune Responses
新型混合计算模型可解开复杂的免疫反应
- 批准号:
10794448 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
解决重组脊髓灰质炎病毒免疫疗法的时空动力学问题
- 批准号:
10676548 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
- 批准号:
10568344 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Uncovering the essential role of host hetero-hexameric ATPases in rhinovirus replication
揭示宿主异六聚体 ATP 酶在鼻病毒复制中的重要作用
- 批准号:
MR/X020371/1 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Research Grant
Immune Programs and Related T Cell Mechanisms of Pulmonary Complications After COVID-19 Illness
COVID-19 疾病后肺部并发症的免疫程序和相关 T 细胞机制
- 批准号:
10886167 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Factors Influencing Pediatric Asthma into Adulthood (FIPA2)
影响成年期小儿哮喘的因素 (FIPA2)
- 批准号:
10778115 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
上呼吸道病毒感染引起的哮喘加重中的鼻肺交互作用
- 批准号:
10733754 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Influence of the nasal microbiome on host susceptibility and response to respiratory viruses
鼻腔微生物组对宿主对呼吸道病毒的易感性和反应的影响
- 批准号:
10595400 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:
Molecular epidemiology of respiratory virus exposure in elementary schools
小学呼吸道病毒暴露的分子流行病学
- 批准号:
10646577 - 财政年份:2023
- 资助金额:
$ 81.55万 - 项目类别:














{{item.name}}会员




